Amgen Pays Array $60 Million Upfront For Its Phase One Type 2 Diabetes Compound
The deal for ARRY-403 includes up to $666 million in milestones, a two-year research-funding agreement and U.S. co-promotion option.
The deal for ARRY-403 includes up to $666 million in milestones, a two-year research-funding agreement and U.S. co-promotion option.